Biomarker-guided treatment for metastatic prostate cancer
Part of Cancer clinical trials.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed prostate cancer under the microscope (prostate adenocarcinoma) and it has spread to distant sites.
- Your cancer is metastatic based on a bone scan or CT/MRI showing lesions in the body.
- You are starting systemic (whole-body) treatment for metastatic disease, either hormone-sensitive new cases or first-line castration-resistant cases.
- Your general health is good enough for trial treatments (ECOG performance score 0 to 2, per the study doctor).
- Recent heart/stroke history, uncontrolled blood pressure, or certain major procedures in the last 6 months may exclude you.
- Your blood counts and organs (including bone marrow and albumin level ≥ 28 g/L) are adequate, and you can follow study visits; you must sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.